BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
我放心你带套猛
发表于 昨天 16:05
121
0
0
Domestic innovative pharmaceutical companies have once again exposed a deep-water bomb.
On October 25th, Yin Min, the Chief Commercial Officer of BeiGene Greater China, a leading domestic innovative pharmaceutical company, was exposed by the media to be under investigation by regulatory agencies. The report stated that industry insiders confirmed the authenticity of this news to the media. After the news came out, BeiGene's stock price fluctuated slightly in the three major capital markets of the Science and Technology Innovation Board, Hong Kong Stock Exchange, and US Stock Exchange in the afternoon, with the largest decline in the Science and Technology Innovation Board market falling by more than 3%.
A reporter from Huaxia Times called the Investor Relations Department of BeiGene, but when the call was answered, it showed that the contact person was not available and needed to leave a message. However, it later showed that the phone mailbox was full and unable to leave a message. As of the time of publication, no external contacts related to BeiGene have responded to the authenticity of the information regarding Yin Min.
The day before, the specific date for the 2024 medical insurance negotiations was announced. In recent years, Yin Min, as the Chief Business Officer of BeiGene Greater China, has appeared multiple times at the medical insurance negotiations. It is unknown whether this well-known pharmaceutical executive will arrive as scheduled this time. Huaxia Times will track the relevant news as soon as possible.
According to official information, Yin Min officially joined BeiGene in January 2022. Prior to this, she had held multiple positions at multinational pharmaceutical companies AstraZeneca and Eli Lilly. She worked at AstraZeneca for nearly 15 years, moving through multiple business departments.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- BlackRock executives harshly comment on 'non farm overhaul': interest rates too high, Fed should 'cut 50' in September!
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Affected by a large-scale strike, Boeing announced a freeze on recruitment and considers granting unpaid leave to employees, managers, and executives for non essential travel
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- Faraday Future: Jia Yueting and other executives purchase 10455 shares of Class A common stock in the company
- Pfizer CEO may meet with key executives of radical investor Starboard Value next week
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
-
第七届中国国际进口博览会即将到来。作为进博会“全勤生”,此次进博会,强生将以“创新于行,关爱于心”为主题,聚焦医疗科技和创新制药两大业务板块,携百余款创新产品亮相医疗器械及医药保健展区7.2馆,其中 ...
- blueskybb
- 昨天 14:16
- 支持
- 反对
- 回复
- 收藏
-
【福特CEO:最近一直开小米SU7】美国福特汽车公司首席执行官(CEO)吉姆法利透露,在过去6个月里他一直开中国小米公司制造的SU7电动汽车,同时也借此思考未来要如何与中国汽车业竞争。他还说,现在已不想再去开原来 ...
- xiaoguaiguai
- 昨天 13:15
- 支持
- 反对
- 回复
- 收藏
-
界面新闻记者 | 崔鹏 10月23日凌晨,高通技术公司在骁龙峰会上宣布推出Snapdragon Cockpit Elite(骁龙座舱至尊版)和Snapdragon Ride Elite(Snapdragon Ride至尊版)两款新型车载平台。 高通汽车、行 ...
- 871
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【台积电明年5纳米以下报价或再涨】据业界人士称,台积电为降低海外厂高营运成本及2纳米部署成本所带来的毛利率冲击,近期已向多家客户释出2025年代工报价,根据客户、产品与产能规模不同,5纳米、4纳米、3纳米代工 ...
- 小延Air
- 昨天 12:38
- 支持
- 反对
- 回复
- 收藏